目的 探讨西黄丸联合XELOX化疗方案治疗结直肠癌的临床疗效。方法 将唐山市中医医院在2024年2月—2026年2月收治的结直肠癌患者共计116例作为研究对象，所有患者以随机数字表分为对照组和治疗组，每组58例。对照组采用XELOX化疗方案治疗，治疗组在对照组基础上口服西黄丸，3 g/次，2次/d。3周为1个疗程，两组持续治疗4个疗程。比较两组的临床治疗效果、体能状态、血液指标，记录不良反应发生情况。结果 对照组的总有效率77.59%明显低于治疗组91.38%，差异有统计学意义（P＜0.05）。治疗后，两组的东部肿瘤协作组（ECOG）评分显著降低（P＜0.05），且治疗组的ECOG评分明显低于对照组（P＜0.05）。两组治疗后的血清癌胚抗原（CEA）、糖类抗原242（CA242）、细胞角蛋白19片段（CYFRA21-1）水平显著降低（P＜0.05），且治疗组治疗后血清CEA、CA242、CYFRA21-1水平低于对照组（P＜0.05）。治疗后，两组的Th1、Th1/Th2明显升高，Th2明显降低（P＜0.05）；治疗组的Th1、Th1/Th2高于对照组，Th2低于对照组（P＜0.05）。治疗组恶心呕吐、白细胞减少、腹泻、末梢神经炎的发生率低于对照组（P＜0.05）。结论 西黄丸联合XELOX化疗方案可提高结直肠癌的疗效，改善体能状态，降低肿瘤标志物，调节Th1/Th2平衡，降低不良反应的发生。

Objective To investigate the clinical efficacy of Xihuang Pills combined with XELOX chemotherapy regimen in treatment of colorectal cancer. Methods 116 Patients with colorectal cancer admitted to Tangshan Traditional Chinese Medicine Hospital from February 2024 to February 2026 were divided into control group and treatment group using a random number table method, with 58 cases each group. The control group was treated with XELOX chemotherapy regimen, while the treatment group received oral administration of Xihuang Pills on the basis of the control group, 3 g/time, twice daily. One course of treatment was 3 weeks, and two groups continued treatment for 4 courses. The clinical treatment efficacy, physical fitness status, and blood indicators were compared between two groups, and the occurrence of adverse reactions were recorded. Results The total effective rate of the control group (77.59%) was significantly lower than that of the treatment group (91.38%), and the difference was statistically significant (P < 0.05). After treatment, the Eastern Tumor Collaboration Group (ECOG) scores in two groups significantly decreased (P< 0.05), and the ECOG score of the treatment group was significantly lower than that of the control group (P < 0.05). After treatment, the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 242 (CA242), and cytokeratin 19 fragment (CYFRA21-1) in two groups were significantly reduced (P< 0.05), and the serum levels of CEA, CA242, and CYFRA21-1 in the treatment group were lower than those in the control group (P < 0.05). After treatment, Th1 and Th1/Th2 levels in two groups significantly increased, while Th2 levels significantly decreased (P < 0.05). The Th1 and Th1/Th2 levels in the treatment group were higher than those in the control group, while Th2 levels were lower than those in the control group (P < 0.05). The incidence of nausea, vomiting, leukopenia, diarrhea, and peripheral neuropathy in the treatment group was lower than that in the control group (P< 0.05). Conclusion The combination of Xihuang Pills and XELOX chemotherapy regimen can improve the efficacy of colorectal cancer, improve physical condition, reduce tumor markers, regulate Th1/Th2 balance, and reduce the occurrence of adverse reactions.

R979.1

河北省中医药管理局科研计划项目（2025132）